Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cyclophos brand of cyclophosphamide

Known as: Cyclophos brand, cyclophos 
brand of cyclophosphamide
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Authors' disclosures of potential conflicts of interest are found at the end of this article. T he management of chronic… Expand
  • table 1
  • table 2
Highly Cited
2012
Highly Cited
2012
Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2006
Highly Cited
2006
Clinically significant interstitial lung disease affects patients with systemic sclerosis (scleroderma) and is a cause of… Expand
2003
2003
We describe successful unrelated cord blood transplantation in a 14-month-old boy with Wiskott-Aldrich syndrome. He had been… Expand
Highly Cited
2002
Highly Cited
2002
Humoral or antibody-mediated rejection in cardiac transplant recipients is mediated by donor-specific cytotoxic antibodies and is… Expand
1990
1990
Abstract Both single-agent cisplatin and the combination of doxorubicin and cyclophosphamide demonstrated moderate activity… Expand
Highly Cited
1982
Highly Cited
1982
  • B. Hales
  • Cancer research
  • 1982
  • Corpus ID: 6882603
Abstract Cyclophosphamide must be metabolically activated to have maximal mutagenic or teratogenic activity. The first step in… Expand
1976
1976
We have used the spleen colony assay system and survival duration studies in male DBA/2 mice with P388 leukemia to study the… Expand
  • table 1
1974
1974
Summary The cytotoxic effect of the combination of vincristine sulfate and cyclophosphamide was quantitated by the spleen colony… Expand
1969
1969
Summary Single doses of nitrogen mustard or cyclophosphamide caused regression of plasmacytomas in hamsters and decreases in the… Expand
  • table 2
  • table 4